-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Deleobuvir
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/863884-77-9.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 863884-77-9 |
| Description | Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor. |
Product Information
| Synonyms | Deleobuvir|863884-77-9|BI 207127|UNII-58BU988K90|58BU988K90|BI207127|BI-207127|1221574-24-8|(E)-3-(2-(1-(((2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-2-propenoic acid|(E)-3-[2-[1-[[[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indol-6-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-propenoic acid|Deleobuvir [USAN:INN]|SCHEMBL900174|SCHEMBL900176|CHEMBL2403318|DTXSID40235516|DB14850|HY-12634|CS-0012113|Q15708312|(2E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl(-1-methyl-1H-benzimidazol-6-yl)prop-2-enoic acid|(E)-3-(2-(1-(2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid|(E)-3-[2-[1-[[[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indol-6-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-propenoicacid|(E)-3-[2-[1-[[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methylindole-6-carbonyl]amino]cyclobutyl]-3-methylbenzimidazol-5-yl]prop-2-enoic acid|2-Propenoic acid, 3-(2-(1-(((2-(5-bromo-2-pyrimidinyl)-3-cyclopentyl-1-methyl-1H-indol-6-yl)carbonyl)amino)cyclobutyl)-1-methyl-1H-benzimidazol-6-yl)-, (2E)- |
| Molecular Weight | 653.57 |
| Molecular Formula | C34H33BrN6O3 |
| Canonical SMILES | CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)C=CC(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7 |
| Boiling Point | 851.4±65.0 °C at 760 mmHg |
| Flash Point | 468.7±34.3 °C |
| Purity | ≥ 98 % |
| Density | 1.5±0.1 g/cm3 |
| Solubility | Soluble in DMSO, not in water |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Assay | Showing weak or no inhibition in specific assays including poliovirus RdRp, mammalian DdRp II and DNA polymerase α, β and γ. |
| Complexity | 1090 |
| Exact Mass | 652.17975 |
| Index Of Refraction | 1.736 |
| In Vitro | Deleobuvir (BI-207127, BI207127) is a potent selective HCV NS5B polymerase inhibitor with an IC50 of 50 nM for GT-1 HCV polymerase activity; Exhibits subgenomic antiviral activity against GT1b and GT1a with EC50s of 11 and 23 nM. |
| Target | HCV |
| Vapor Pressure | 0.0±0.3 mmHg at 25°C |
| XLogP3-AA | 5.6 |